Innovations In Clinical Neuroscience

HOTTOP Multiple Sclerosis MAR 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 8 of 23

9 Hot Topics in Multiple Sclerosis [March 2018] March is MS Awareness Month Highlighting the history of multiple sclerosis, where research is going, and the general interest of the MS community M arch is Multiple Sclerosis (MS) Awareness Month, as declared by the Multiple Sclerosis Association of America. The mission of the association is to increase awareness of the disease and how it impacts those who have it. 1 Research for MS has made significant strides since the first case of the disease was recorded in 1421. 2 While there remains no cure for MS, many new treatments are being developed and released to the public to help prevent relapses, manage symptoms, and speed recovery. There is a wide range of symptoms patients with MS might experience, and, in some individuals, the disease can be present for years before symptoms occur. MS often affects a patient's cognitive and physical abilities, making daily activities difficult during periods of relapse. Take a look at some key moments in the history of multiple sclerosis and click the link at the end of the description for a full timeline from the National Multiple Sclerosis Society. 3 1421 — The first case of MS was documented nearly 600 years ago. Arguably, however, the first official case of MS was Augustus d'Este, King George III of England's grandson. D'Este died in 1848, more or less marking the beginning of research into the disease. 4 1868 — The first medical description of the disease was developed by Jean- Martin Charcot, a French neurologist. Charcot was the first to identify and connect some of the symptoms to the central nervous system. He attempted to treat MS with gold chloride, zinc, sulfate, and silver nitrate. 1943— Studies on myelin in brain tissue began as early as the 1860s, but it wasn't until 1943 that researchers completed a detailed description of myelin's composition. Three years later, the National Multiple Sclerosis Society was formed. 1969— This was the year the National Multiple Sclerosis Society helped fund a study on steroid adrenocorticotropic hormone (ACTH), the first drug shown to help speed recovery from relapses in patients with MS. 1993— Betaseron (interferon beta- 1b) was approved in 1993 by the United States Food and Drug Administration (FDA) for patients with relapsing remitting MS. 2000— Seven years later, in 2000, Novantrone (mitoxantrone) was approved by the FDA for patients with worsening forms of MS. 2009— Extavia, another interferon beta-1b) drug for treatment of MS gained FDA approval in 2009. 2010— Just one year later, in 2010, Gilenya was approved by the FDA and became the first oral treatment for MS. Additional oral treatments were approved in the United States over the next few years. 2016— The International Consortium of Multiple Sclerosis Genetics in 2016 successfully identified 200 genetic variations linked to MS, a breakthrough in the connection between genetics and the disease. 2017— Ocrelizumab was FDA- approved in 2017, becoming the first disease-modifying therapy for primary progressive MS. It can also treat relapsing forms of MS, making it the only drug on the market that can treat both forms of MS. Click * for more information. A Timeline of the History of Multiple Sclerosis

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - HOTTOP Multiple Sclerosis MAR 2018